The Federal Health and Biological Agency (FMBA) on March 28 formally introduced a drug to treat the SARS-CoV-2 virus that causes acute respiratory tract infection COVID-19, Sputnik reported.
FMBA is implementing “an effective and safe model to prevent the spread of SARS-CoV-2 on the basis of Mefloquine, which will not only help overcome the peak of the epidemic, but will also effectively manage the disease.” in the future, “the agency stated.
Accordingly, the FMBA Pharmazia Research and Production Center has studied based on the experience of China and France to develop a COVID-19 treatment regimen based on Mefloquine malaria prevention and treatment drug.
While experts around the world are trying to create a new vaccine to fight the SARS-CoV-2 virus, there are also efforts to reuse existing drugs to treat patients. Russia and the preparation of Mefloquine are an example.
This drug has been around since the 1970s. After its preparation, it can prevent the virus from spreading in the body. In addition, the immunosuppressive effect of Mefloquine may prevent the inflammatory response caused by SARS-CoV-2.
The announcement came at a time when Russia recorded a total of 1,264 COVID-19 infections in 62 regions with four deaths. In the past 24 hours, Russia has added 228 cases of this dangerous epidemic.
Earlier on March 26, Russian President Vladimir Putin announced that the country would defeat COVID-19 in the next two or three months. “We can completely overcome this situation, and I hope we can overcome it earlier than expected time,” Putin said.
A week ago, the Russian Ministry of Health issued a statement saying scientists in Russia had succeeded in fully decoding the genome of the SARS-CoV-2 virus. The first complete genome of the SARS-CoV-2 virus was decoded from a patient sample with a COVID-19 patient in Russia.